Q-omics provides the consensus-scored ZNF490 profile across patient tissues and cancer cell-line models. ZNF490 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF490 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, ZNF490 RNA expression shows 21,364 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where ZNF490 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF490 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF490 survival associations across molecular data types. ZNF490 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF490 RNA expression–survival associations across cancer types. High ZNF490 expression shows favorable associations in KIRC, HNSC, STAD, LUAD, SCLC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF490 RNA expression.
This table summarizes ZNF490 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF490. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF490 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, BRCA, BLCA and LIHC. The COAD box plot shows higher ZNF490 RNA expression in tumor versus normal tissue (log2 FC = +0.215, t-test p < 0.001).
This table shows molecular features associated with ZNF490 in patient tissues and cancer cell lines. In patient samples, ZNF490 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF490 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
